MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)

NCT03846219 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing-Remitting Multiple Sclerosis (RRMS)

Interventions

DRUG: IMU-838 (30 mg/day)
DRUG: IMU-838 (45 mg/day)
DRUG: Placebo
DRUG: IMU-838 (10 mg/day)

Sponsor

Immunic AG